Literature DB >> 2757917

Prognostic factors and classification in multiple myeloma.

J F San Miguel1, J Sànchez, M Gonzalez.   

Abstract

Analyses of prognostic factors have allowed the design of staging systems in different haematological disorders. In a series of 220 patients with multiple myeloma, univariate analysis showed that nine parameters had a significant adverse effect on survival; poor performance status (Karnowsky scaling system less than 70%), infections before diagnosis, renal impairment (assessed either by creatinine clearance greater than 2 mg dl-1 or urea greater than 40 mg dl-1), serum calcium (greater than 10 mg dl-1), severe anaemia (less than 8.5 g dl-1), the presence of Bence-Jones proteinuria, failure to achieve complete remission, more than 40% plasma cells in bone marrow and a low paraprotein index (monoclonal component/% plasma cells: P less than 0.09). In addition, this index correlated significantly with all the other prognostic factors except performance status. The best combination of disease characteristics selected by means of the Cox regression proportional hazards method were performance status and creatinine levels. Additionally, by factor analysis of principal components we obtained a regression equation that included creatinine levels, haemoglobin, performance status and paraprotein index. Using this it was possible to separate the series of patients into three risk categories: A (65 patients), B (69 patients) and C (65 patients) with a median survival of 41, 24 and 12 months, respectively. The model provided similar results to those of the British Medical Research Council, whereas the staging systems proposed by Durie and Salmon, Merlin et al. and Carbone et al. had a lower discriminant value in our series.

Entities:  

Mesh:

Year:  1989        PMID: 2757917      PMCID: PMC2246952          DOI: 10.1038/bjc.1989.23

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

Review 1.  The current status and future prospects of treatment for multiple myeloma.

Authors:  B G Durie; S E Salmon
Journal:  Clin Haematol       Date:  1982-02

2.  Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.

Authors:  F Cavagnaro; J M Lein; S Pavlovsky; J O Becherini; J E Pileggi; E Q Micheo; C Jait; A Musso; A Suárez; M Pizzolato
Journal:  Cancer Treat Rep       Date:  1980-01

3.  Bone marrow percentage of plasma cells in the staging of monoclonal gammopathies.

Authors:  D Vercelli; R Di Guglielmo; G Guidi; L Scolari; L Buricchi; F Cozzolino
Journal:  Nouv Rev Fr Hematol       Date:  1980

4.  Prognostic factors in multiple myeloma: a retrospective study using conventional statistical methods and a computer program.

Authors:  Y Matzner; J Benbassat; A Polliack
Journal:  Acta Haematol       Date:  1978       Impact factor: 2.195

5.  Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.

Authors:  B Simonsson; C F Källander; G Brenning; A Killander; A Ahre; J S Gronowitz
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

6.  Prognostic factors in multiple myeloma treated with prednisolone and sequential melphalan and ifosfamide: MIP combination chemotherapy.

Authors:  T Adachi; K Asano; T Sezaki; I Takahashi; I Kimura
Journal:  Acta Med Okayama       Date:  1982-02       Impact factor: 0.892

7.  A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.

Authors:  G Merlini; J G Waldenström; S D Jayakar
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

Review 8.  Classification and prognostic variables in myelomatosis.

Authors:  O P Hansen; D A Galton
Journal:  Scand J Haematol       Date:  1985-07

9.  A comparison of two staging systems for myeloma.

Authors:  D Vercelli; F Cozzolino; R Di Guglielmo
Journal:  Nouv Rev Fr Hematol       Date:  1981

10.  Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

Authors:  B G Durie; S E Salmon; T E Moon
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

View more
  4 in total

1.  The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.

Authors:  M G Alexandrakis; F H Passam; C Dambaki; C A Pappa; E N Stathopoulos
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

Review 2.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

3.  Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Miguel-Garcia; E Matutes; F Tarin; J Garcia-Talavera; A Miguel-Sosa; F Carbonell; D Catovsky
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

4.  Myeloma--results of treatment 1986-1990.

Authors:  P Kettle; L Ranaghan; G M Markey; J H Robertson; Z R Desai; C Bharucha; T C Morris
Journal:  Ulster Med J       Date:  1993-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.